Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravesical therapy.

H W Herr1

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York.

Hematology/Oncology Clinics of North America
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radical cystectomy and orthotopic urinary reconstruction in patients with bladder cancer after renal transplantation: clinical outcomes and description of technique.

Transplantation proceedings·2013
Same author

Bedside sphincterometry.

Urology·2011
Same author

Selecting clinical research projects for the urologic oncologist.

Urologic oncology·2011
Same author

Uncertainty and outcome of invasive bladder tumors.

Urologic oncology·2011
Same author

Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality).

BJU international·2003
Same author

A comparison of hospital-based charges following partial and radical nephrectomy.

Urologic oncology·2002
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Intravesical therapy, particularly bacillus Calmette-Guerin (BCG), is crucial after surgery for superficial bladder tumors. BCG effectively eliminates remaining cancer cells, prevents recurrence, and stops disease progression, outperforming chemotherapy.

Area of Science:

  • Urology
  • Oncology
  • Immunotherapy

Background:

  • Superficial bladder tumors require intravesical therapy post-resection.
  • Therapy aims to eradicate disease, prevent recurrence, and inhibit progression.
  • Bacillus Calmette-Guerin (BCG) is a key intravesical agent.

Purpose of the Study:

  • To evaluate the efficacy of intravesical therapy for superficial bladder tumors.
  • To compare bacillus Calmette-Guerin (BCG) with chemotherapeutic drugs.
  • To highlight BCG's role in preventing tumor recurrence and progression.

Main Methods:

  • Intravesical administration of agents post-transurethral resection.
  • Comparative analysis of treatment outcomes.
  • Monitoring for disease recurrence and progression.

Related Experiment Videos

Main Results:

  • Bacillus Calmette-Guerin (BCG) demonstrated effectiveness in eradicating disease.
  • BCG showed superiority over chemotherapeutic agents.
  • BCG successfully inhibited tumor recurrence and progression.

Conclusions:

  • Intravesical bacillus Calmette-Guerin (BCG) is a superior adjunctive therapy for superficial bladder cancer.
  • BCG is effective in preventing recurrence and progression to invasive disease.
  • BCG offers a more favorable outcome compared to intravesical chemotherapy.